Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309623 | 1.00 | TPH1 (0.70) | TPH1 | |
| SCHEMBL309622 | 1.00 | TPH1 (0.70) | TPH1 | |
| SCHEMBL1129126 | 0.82 | TPH1 (0.55) | TPH1 | |
| SCHEMBL1880944 | 0.82 | TPH1 (0.55) | TPH1 | |
| SCHEMBL308510 | 0.79 | TPH1 (1.00) | TPH1 | |
| SCHEMBL870567 | 0.79 | TPH1 (0.74) | TPH1 | |
| SCHEMBL14969125 | 0.79 | TPH1 (1.00) | TPH1 | |
| SCHEMBL3408238 | 0.79 | TPH1 (1.00) | TPH1 | |
| SCHEMBL870566 | 0.79 | TPH1 (0.74) | TPH1 | |
| SCHEMBL14969126 | 0.79 | TPH1 (1.00) | TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | LEXICON PHARMACEUTICALS, INC. | 2012-12-13 | — | — | US | disclosed |
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120157484-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2012-06-21 | — | — | US | disclosed |
| US-8093291-B2 | Methods of using and compositions comprising tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8063057-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TERSERA THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-7875622-B2 | administering to a patient A therapeutically effective amounts of an endothelin receptor antagonist e.g. ambrisentan, bosentan etc. and (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid to treat pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100317664-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | TERSERA THERAPEUTICS LLC | 2010-11-04 | — | — | US | disclosed |
| US-7723345-B2 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2009-01-01 | — | — | US | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TPH1, PAH, TPH2 | TPH1 1/4885 |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | TPH1 1/4885 |
| US-20100280054-A1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | AADAT, HNMT, TPH1 | TPH1 3/4885 |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | TPH1, TPH2, HNMT | TPH1 1/4885 |
| US-20120157484-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HNMT | TPH1 1/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | TPH1 3/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | TPH1 1/4885 |
| US-20110112094-A1 | Methods of Treating Pulmonary Hypertension | TPH1, TPH2, PTGIS | TPH1 1/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | TPH1 1/4885 |
| US-20100317664-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, SLC10A2 | TPH1 1/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | TPH1 1/4885 |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, MAOB | TPH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.